We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New RNA-Based Measure Predicts Mortality Risk and Tracks Aging

By LabMedica International staff writers
Posted on 30 Jul 2025

Aging is a complex biological process that affects multiple systems in the body and increases the risk of disease and death. More...

Scientists have long sought accurate ways to measure biological aging, which can help assess individual health risks and guide interventions. Traditional measures like DNA methylation and blood biomarkers have limitations. RNA, which reflects real-time gene activity, offers another path, but existing RNA-based aging tools often rely on small or non-representative datasets. Accurate, flexible, and scalable tools that can track biological aging across diverse populations remain in high demand. Now, researchers have developed a new solution that uses RNA to predict a person’s risk of dying and detect changes in their biological age as their health evolves.

The RNA-based aging tool, called Transcriptomic Mortality-risk Age (TraMA), was developed by researchers from the University of Southern California (Los Angeles, CA, USA) by analyzing RNA sequencing data from nearly 4,000 U.S. adults aged 50 and older. TraMA estimates biological aging based on gene expression profiles and was developed using modern sequencing technology and a nationally representative dataset. Unlike previous RNA-based aging measures, TraMA offers greater reliability and captures key biological changes associated with inflammation, immune function, and kidney and brain health. The tool is also responsive to behavioral and socioeconomic factors, with older TraMA scores linked to smoking, obesity, and low physical activity. It can track biological aging over time, offering insight into how lifestyle and health influence gene expression patterns.

TraMA was validated using data from the Long-Life Family Study and multiple publicly available datasets involving patients with diabetes, sepsis, and cancer. The findings, published in Aging (Aging-US), showed that TraMA is a strong and independent predictor of early death, multiple chronic diseases, poor cognitive function, and difficulties with daily activities. It outperformed well-known biological aging measures like GrimAge and PhenoAge by capturing distinct and complementary aspects of aging. TraMA also proved effective across different populations and sample sizes, including both large-scale surveys and small clinical cohorts. Going forward, researchers hope to use TraMA to enable more precise investigations into the interplay between genes, environment, and health outcomes, ultimately helping extend human lifespan.

“TraMA is likely to be of particular value to researchers interested in understanding the biological processes underlying health and aging, and for social, psychological, epidemiological, and demographic studies of health and aging,” said Eric T. Klopack, lead author of the TraMA study.


Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Collection and Transport System
PurSafe Plus®
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: Automated cell imaging discriminates CD8+ T cells according to natalizumab treatment outcome in MS patients (B Chaves et al., Nat Commun 16, 5533 (2025). DOI: 10.1038/s41467-025-60224-3)

Novel Tool Predicts Most Effective Multiple Sclerosis Medication for Patients

Multiple sclerosis (MS) is a chronic autoimmune and degenerative neurological disease that affects the central nervous system, leading to motor, cognitive, and mental impairments. Symptoms can include... Read more

Technology

view channel
Image: The SWITCH hybrid pipette is designed to simplify and accelerate pipetting tasks (Photo courtesy of INTEGRA)

Hybrid Pipette Combines Manual Control with Fast Electronic Aliquoting

Manual pipettes offer the control needed for delicate tasks such as mixing or supernatant removal, but typically fall short in repetitive workflows like aliquoting. Electronic pipettes solve this problem... Read more

Industry

view channel
Image: ELITechGroup’s unique Real-Time PCR technologies include the revolutionary Minor Groove Binder (Photo courtesy of ELITechGroup)

ELITech and Hitachi High-Tech to Develop Automated PCR Testing System for Infectious Diseases

Molecular testing has become central to diagnosing and monitoring infectious diseases by analyzing genetic information. The use of PCR during the COVID-19 pandemic showed its value, but traditional systems... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.